Results 31 to 40 of about 31,481 (258)

Hypobaric hypoxia-related impairment of pulmonary surfactant proteins A and D did not favour Pneumocystis carinii Frenkel 1999 growth in non-immunocompromised rats

Parasite, 2008
It has been suggested that patients with pulmonary surfactant impairment are more susceptible to Pneumocystis infection than healthy controls. Owing the fact that most patients with pulmonary surfactant impairment also suffer from hypoxia, we explored ...
Vives M.F., Caspar-Bauguil S., Aliouat E.M., Escamilla R., Perret B., Dei-Cas E., Prévost M.C.   +6 more
doaj   +1 more source

Sulfa Resistance and Dihydropteroate Synthase Mutants in Recurrent Pneumocystis carinii Pneumonia

Emerging Infectious Diseases, 2003
Failure of sulfa or sulfone prophylaxis is associated with mutations in Pneumocystis carinii gene coding for dihydropteroate synthase (DHPS). The DHPS genotype was analyzed in AIDS patients who had two separate episodes of P. carinii pneumonia.
Aimable Nahimana, Meja Rabodonirina, Jannik Helweg-Larsen, Isabelle Meneau, Patrick Francioli, Jacques Bille, Philippe M. Hauser   +6 more
doaj   +1 more source

PRIMACENES: novel non-cytotoxic primaquine-ferrocene conjugates with anti-Pneumocystis carinii activity [PDF]

, 2010
Primacenes, novel ferrocene-primaquine conjugates, were synthesized and screened for their antimalarial and anti-pneumocystis activity. Primacenes obtained by coupling primaquine amino acid derivatives to ferrocenoic acid were significantly active ...
Jiri Gut, Joana Matos, Margaret S Collins, Melanie T Cushion, Nuno Vale, Paula Gomes, Philip J Rosenthal, Rui Moreira   +7 more
core   +1 more source

Comparative genomics suggests that the fungal pathogen pneumocystis is an obligate parasite scavenging amino acids from its host's lungs. [PDF]

PLoS ONE, 2010
Pneumocystis jirovecii is a fungus causing severe pneumonia in immuno-compromised patients. Progress in understanding its pathogenicity and epidemiology has been hampered by the lack of a long-term in vitro culture method.
Philippe M Hauser, Frédéric X Burdet, Ousmane H Cissé, Laurent Keller, Patrick Taffé, Dominique Sanglard, Marco Pagni   +6 more
doaj   +1 more source

Risk factors for drug resistant tuberculosis in Leicestershire - poor adherence to treatment remains an important cause of resistance [PDF]

, 2013
In the light of rising numbers of tuberculosis (TB) cases in the United Kingdom, the problem of anti-tubercular drug resistance remains a significant concern.
Hayward, AC, Monk, PN, Neal, KR, Pritchard, AJ   +3 more
core   +2 more sources

Aerosolised pentamidine for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome Aerosol de pentamidina no tratamento da pneumonia por Pneumocystis carinii em pacientes com a síndrome da imunodeficiência adquirida

Revista do Instituto de Medicina Tropical de São Paulo, 1990
The goal of this study was to evaluate inhaled pentamidine for the treatment of patients with mild and moderate Pneumocystis carinii pneumonitis. Eight adults with AIDS and pneumocystis pneumonia (4 with a first episode and 4 with a repeat pneumocystosis)
Adriana Weinberg, Sebastião A. Dantonio, Maria Irma S. Duarte, Wilson L. Pedreira Jr., Antonio A. Barone, Shinishi Ishioka   +5 more
doaj   +1 more source

Ploidy of cell-sorted trophic and cystic forms of Pneumocystis carinii.

PLoS ONE, 2011
Once regarded as an AIDS-defining illness, Pneumocystis pneumonia (PcP) is nowadays prevailing in immunocompromised HIV-negative individuals such as patients receiving immunosuppressive therapies or affected by primary immunodeficiency.
Anna Martinez, El Moukhtar Aliouat, El Moukhtar Aliouat, Annie Standaert-Vitse, Elisabeth Werkmeister, Muriel Pottier, Claire Pinçon, Eduardo Dei-Cas, Cécile-Marie Aliouat-Denis   +8 more
doaj   +1 more source

Limited asymptomatic carriage of Pneumocystis jiroveci in human immunodeficiency virus-infected patients [PDF]

, 2003
Forty-seven bronchoalveolar lavage fluid samples from 16 human immunodeficiency virus (HIV)-infected patients were used to test the latency model of Pneumocystis infection in the human host.
Ambrose, HE, Denis, CM, Lindley, AR, Miller, RF, Wakefield, AE   +4 more
core  

Enfortumab vedotin plus pembrolizumab in treatment‐naïve metastatic urothelial carcinoma patients: An Austrian real‐world analysis

International Journal of Cancer, Volume 158, Issue 6, Page 1654-1665, 15 March 2026.
What's new? New antibody‐drug conjugates (ADCs) and immunotherapies have helped expand treatment options for urothelial carcinoma (UC). Clinical trials suggest that the ADC enfortumab vedotin (EV) and the immunotherapeutic agent pembrolizumab, when used in combination, are especially effective against UC.
Dora Niedersuess‐Beke, Karl Mayrhofer, Johanna Krauter, Johannes Franke, Dominic Vais, Maximillian Pallauf, David Kiesl, Ferdinand Luger, Jacob Pfuner, Angelika Terbuch, Thomas Bauernhofer, Jasmin Spielgelberg, Andreas Banner, Stefan Aufderklamm, Clemens Wiesinger, Susanne Schnabel, Simon Peter Gampenrieder, Josef Mühlmann, Sonia Vallet, Sabine Weibrecht, Franz Stoiber, Haleh Andalibi, Harun Fajkovic, Hossein Taghizadeh, Jan Miechowiecki, Roman Taedcke, Daniel Heintel, Shahrokh F. Shariat, Martin Pichler, Wolfgang Hilbe, Renate Pichler   +30 more
wiley   +1 more source

Basic biology of Pneumocystis carinii: a mini review

Memorias do Instituto Oswaldo Cruz, 2005
Basic aspects of cell biology of Pneumocystis carinii are reviewed with major emphasis on its life cycle and the structural organization of the trophozoites and cyst forms.
Wanderley de Souza, Marlene Benchimol
doaj   +1 more source